Skip to main content

Table 3 Univariate Cox PH regression models for local/regional recurrence(LRR)-free survival (Number = 819).

From: Implications of constructed biologic subtype and its relationship to locoregional recurrence following mastectomy

Variable

LRR-free

(Number = 800)

LRR (Number = 19)

HR (95%CI)

P-value

Age at diagnosis

    

   > 50

522

7

reference

 

   < 50

278

12

3.22 (1.28 to 8.33)

0.01

T stage

    

   T1

604

9

reference

 

   T2

187

8

2.95 (1.14-7.64)

0.03

   T3

9

2

19.8 (4.24-92.3)

< 0.01

Pathologic stage

    

   I

450

4

Reference

 

   IIA and IIB

335

11

3.74 (1.19-11.7)

0.02

   IIIA, IIIB, IIIC and IV

15

4

31.8 (7.94- 127)

< 0.01

Number of positive lymph nodes

    

   0

579

7

reference

 

   1-3

209

10

3.94 (1.50-10.3)

0.01

   > 4

8

2

23.3 (4.83- 112)

< 0.01

Modified Black's nuclear grade

    

   3 versus 1,2

  

6.93 (2.30-20.88)

< 0.01

ER or PR

    

   Negative

137

11

reference

 

   Positive

648

8

0.15 (0.06-0.38)

< 0.01

HER2+

    

   Negative

653

15

reference

 

   Positive

105

4

1.64 (0.54-4.94)

0.38

Lymphovascular invasion

    

   Negative

555

9

reference

 

   Positive

127

10

5.08 (2.06-12.5)

< 0.01

Received trastuzumab (in HER2+ patients)

    

   No

78

2

reference

 

   Yes

26

2

3.87 (0.53-28.1)

0.18

Systemic therapy

    

   No

141

3

reference

 

   Yes

658

16

1.11 (0.32-3.80)

0.87

Constructed Subtype

    

   HR+/HER2-

569

5

reference

 

   HR+/HER2+

54

3

6.25 (1.49-26.2)

0.01

   HR-/HER2+

50

1

2.24 (0.26-19.2)

0.46

   HR-/HER2-

84

10

13.6 (4.63-39.7)

< 0.01

  1. CI, confidence interval; ER, estrogen receptor; HER2, human epidermal growth receptor 2; PR, progesterone receptor.